Continue to site >
Trending ETFs

Name

As of 03/15/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$31.53

$138 M

0.00%

1.14%

Vitals

YTD Return

7.6%

1 yr return

13.8%

3 Yr Avg Return

6.4%

5 Yr Avg Return

10.0%

Net Assets

$138 M

Holdings in Top 10

49.2%

52 WEEK LOW AND HIGH

$31.7
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 1.14%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover N/A

Redemption Fee N/A


Min Investment

Standard (Taxable)

$1,000,000

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund


Name

As of 03/15/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$31.53

$138 M

0.00%

1.14%

HLHIX - Profile

Distributions

  • YTD Total Return 7.6%
  • 3 Yr Annualized Total Return 6.4%
  • 5 Yr Annualized Total Return 10.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.28%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Virtus KAR Health Sciences Fund
  • Fund Family Name
    Allianz Funds
  • Inception Date
    Jul 13, 2020
  • Shares Outstanding
    N/A
  • Share Class
    Instl
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Peter Pirsch

Fund Description

The fund pursues long-term capital appreciation in health sciences-related companies. The fund invests in a select group of health science-related companies believed by the fund’s subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive.

The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. Although the fund may invest in companies of any market capitalization, the fund does not currently intend to invest more than 15% of its assets in companies with market capitalizations below $1 billion. The fund may invest in U.S. and non-U.S. companies. The fund may invest in securities issued in initial public offerings (IPOs). Generally, the fund invests in approximately 25 to 40 securities at any given time.

Read More

HLHIX - Performance

Return Ranking - Trailing

Period HLHIX Return Category Return Low Category Return High Rank in Category (%)
YTD 7.6% -13.3% 20.7% 17.18%
1 Yr 13.8% -19.1% 38.0% 63.19%
3 Yr 6.4%* -31.4% 13.8% 25.00%
5 Yr 10.0%* -3.8% 14.2% 19.85%
10 Yr N/A* -0.7% 13.8% 35.71%

* Annualized

Return Ranking - Calendar

Period HLHIX Return Category Return Low Category Return High Rank in Category (%)
2023 3.0% -12.6% 19.0% 50.92%
2022 -19.1% -53.9% 3.2% 80.77%
2021 3.1% -39.6% 24.2% 35.90%
2020 -0.7% -13.6% 178.2% 94.04%
2019 18.8% 3.8% 63.8% 68.89%

Total Return Ranking - Trailing

Period HLHIX Return Category Return Low Category Return High Rank in Category (%)
YTD 7.6% -13.3% 20.7% 17.18%
1 Yr 13.8% -19.1% 38.0% 63.19%
3 Yr 6.4%* -31.4% 13.8% 25.00%
5 Yr 10.0%* -3.8% 14.2% 19.85%
10 Yr N/A* -0.7% 13.8% 34.88%

* Annualized

Total Return Ranking - Calendar

Period HLHIX Return Category Return Low Category Return High Rank in Category (%)
2023 3.0% -12.6% 19.0% 71.78%
2022 -11.7% -53.9% 3.7% 50.00%
2021 25.7% -33.9% 26.0% 1.92%
2020 14.1% -0.7% 180.6% 78.81%
2019 27.1% 4.6% 63.8% 43.70%

NAV & Total Return History


HLHIX - Holdings

Concentration Analysis

HLHIX Category Low Category High HLHIX % Rank
Net Assets 138 M 6.16 M 45 B 68.10%
Number of Holdings 29 23 413 96.93%
Net Assets in Top 10 70.1 M 2.07 M 20.4 B 67.48%
Weighting of Top 10 49.24% 18.1% 77.0% 44.79%

Top 10 Holdings

  1. Eli Lilly Co 9.27%
  2. UnitedHealth Group Inc 5.43%
  3. IDEXX Laboratories Inc 4.81%
  4. AbbVie Inc 4.72%
  5. Cooper Cos Inc/The 4.71%
  6. Zoetis Inc 4.41%
  7. Merck Co Inc 4.08%
  8. Vertex Pharmaceuticals Inc 4.04%
  9. West Pharmaceutical Services Inc 3.93%
  10. Danaher Corp 3.83%

Asset Allocation

Weighting Return Low Return High HLHIX % Rank
Stocks
99.17% 87.17% 106.13% 36.20%
Cash
0.83% 0.00% 32.99% 68.71%
Preferred Stocks
0.00% 0.00% 7.86% 62.58%
Other
0.00% -22.99% 17.73% 60.74%
Convertible Bonds
0.00% 0.00% 0.37% 49.37%
Bonds
0.00% 0.00% 12.39% 50.92%

Stock Sector Breakdown

Weighting Return Low Return High HLHIX % Rank
Healthcare
96.35% 59.26% 100.00% 95.57%
Basic Materials
2.90% 0.00% 7.16% 4.43%
Consumer Defense
0.74% 0.00% 25.73% 3.16%
Utilities
0.00% 0.00% 0.00% 44.94%
Technology
0.00% 0.00% 22.69% 48.73%
Real Estate
0.00% 0.00% 5.89% 47.47%
Industrials
0.00% 0.00% 7.02% 48.73%
Financial Services
0.00% 0.00% 1.60% 61.39%
Energy
0.00% 0.00% 0.00% 44.94%
Communication Services
0.00% 0.00% 9.11% 48.10%
Consumer Cyclical
0.00% 0.00% 1.92% 47.47%

Stock Geographic Breakdown

Weighting Return Low Return High HLHIX % Rank
US
99.17% 66.21% 104.41% 23.31%
Non US
0.00% 0.00% 29.78% 77.91%

HLHIX - Expenses

Operational Fees

HLHIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 1.14% 0.08% 4.28% 45.40%
Management Fee 0.80% 0.03% 1.25% 70.55%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.10% 0.03% 0.25% 34.21%

Sales Fees

HLHIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

HLHIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HLHIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover N/A 0.00% 238.00% 89.94%

HLHIX - Distributions

Dividend Yield Analysis

HLHIX Category Low Category High HLHIX % Rank
Dividend Yield 0.00% 0.00% 6.98% 64.42%

Dividend Distribution Analysis

HLHIX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual SemiAnnual Annual

Net Income Ratio Analysis

HLHIX Category Low Category High HLHIX % Rank
Net Income Ratio 0.28% -2.54% 1.85% 20.51%

Capital Gain Distribution Analysis

HLHIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

HLHIX - Fund Manager Analysis

Managers

Peter Pirsch


Start Date

Tenure

Tenure Rank

Mar 22, 2018

4.19

4.2%

Mr. Pirsch is a senior portfolio manager, a senior analyst and a director with Allianz Global Investors, which he joined in 2018. He has management and research responsibilities for the Health Care team. Mr. Pirsch has 20 years of investment-industry experience. He previously worked at Aptigon Capital, Visium Asset Management, Surveyor Capital, Fred Alger Management and C.R. Bard. Before that, Mr. Pirsch was an associate director at UBS Investment Bank and an analyst at Wells Fargo. He has a B.A. in economics and international relations from Bucknell University, and an M.B.A. with a certificate in health sector management from Duke University, Fuqua School of Business. Mr. Pirsch is a CFA charterholder.

Christopher Chin


Start Date

Tenure

Tenure Rank

Aug 27, 2020

1.76

1.8%

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.84 0.25